Chemicals

Olam’s Saudi-Singapore IPO is food for the future

31 May 2023

A $1 bln dual listing of its agri unit is delayed. A pause may help Saudi justify what it paid for a 35% stake. Yet the float will improve the company’s financial strength and its ability to shore up food security in the Gulf, so there’s good reason to get this complex deal done.

War on cow farts is stinky but necessary job

24 Mar 2023

Cattle’s digestion is a big driver of harmful gas emissions. To curb them, New Zealand is taxing farmers and Europe may shrink livestock numbers. Both steps have angered harvesters and may inflate food prices. The noise will teach consumers to treat beef like fossil fuels.

Bayer’s sunk boss leaves high water mark

21 Mar 2023

In one of his last acts before bowing to activist pressure, Werner Baumann is pledging the $60 bln drugs-to-seeds company will slash rice’s H2O needs by 25%. Leaving aside his legacy as the architect of the Monsanto deal, his ambition is worth emulating.

A $5 bln cleaning deal uncovers buyout dirty work

8 Mar 2023

Diversey, a maker of hand sanitizers and floor sealers, broke through the M&A dry spell to find a buyer. As part of the sale, majority owner Bain will accept a discount and roll over some of its stake. It’s a sign of just how much elbow grease it takes in private equity nowadays.

Capital Calls: Adobe’s lose-lose Figma bind

24 Feb 2023

Concise views on global finance: Shareholders in the $160 bln design technology firm seem to have decided that the only thing worse than doing its blockbuster deal for rival Figma is losing it.

Syngenta jumbo IPO will sow seeds of doubt

14 Feb 2023

A Shanghai listing this year may value the pesticides and seeds maker at a chunky $66 bln. The group’s role in feeding a growing global population will please investors. But its reliance on toxic weedkillers that are losing favour in Europe poses a long-term threat.

Capital Calls: Adidas kitchen sink

10 Feb 2023

Concise views on global finance: Shares in the sportswear maker fell 11% amid forecasts of a high-single-digit decline in sales in 2023.

Bayer’s new CEO plants seed of future breakup

9 Feb 2023

Bowing to pressure from activist investor Jeff Ubben, the $66 bln drugs-to-seeds maker is replacing embattled boss Werner Baumann. Ditching the architect of the ill-advised Monsanto deal makes sense. Hiring pharma expert Bill Anderson suggests the crop division may be spun off.

Capital Calls: AI lessons, Robots, Streaming wars

8 Feb 2023

Concise views on global finance: Textbook rental company Chegg becomes an early victim of ChatGPT fears; a short supply of U.S. workers makes automation look even more appealing; Warner Bros Discovery flips the script on its deal logic and will keep HBO Max as a separate service.

Bayer’s rude health lays better path for breakup

11 Jan 2023

Activists including Jeff Ubben are piling into the $58 bln German seed and drug maker. Its cheap share price, thanks to the dire Monsanto deal, has for years dangled the promise of a lucrative carve-up. Improvements in the pharma unit and a CEO change make it more likely now.

Cheaper gas is temporary salve for Europe Inc

9 Jan 2023

Warm winter days and enough reserves to offset Russian imports have halved the fuel’s cost. Yet Europe’s energy security also hinges on abundant liquefied natural gas purchases. As China’s fuel-guzzling economy reopens post-Covid, industrial giants like BASF may still suffer.

Capital Calls: ADNOC chemicals push

21 Dec 2022

Concise views on global finance: The Abu Dhabi National Oil Company seeks to sharpen its focus on petrochemicals by buying a 25% stake in $16 bln Austrian oil group OMV.

Capital Calls: Brenntag M&A gambit

20 Dec 2022

Concise views on global finance: The $9 bln German chemicals group’s talks with U.S. peer Univar have left it stuck with an activist

Capital Calls: Transatlantic chemicals deal

28 Nov 2022

Concise views on global finance: A potential acquisition of Univar by $10 bln German chemical distributor Brenntag makes sense, but investors may fear a bidding war.

Europe’s industrial mess has protectionist endgame

26 Oct 2022

Manufacturers like Germany’s $42 bln BASF face a toxic brew of high energy prices at home and rising risks in China. That implies a freeze on new investment, and a loss of market share to foreign players. To stop that, European states may ultimately intervene with tariffs.

Capital Calls: Peloton races tough economic cycle

6 Oct 2022

Concise views on global finance: The $2.9 bln fitness company is laying off staff for the fourth time this year in a turnaround bid for survival.

Russia is giving German industry a slow puncture

27 Jul 2022

Industrial users of gas are in the firing line as Moscow halts supply. Companies like BASF face a hit from higher input costs and energy rationing, rather than a Uniper-style bailout. The problem for Berlin is that sustained high prices could make production head elsewhere.

Capital Calls: Bank stress tests, Japan inflation

24 Jun 2022

Concise views on global finance: U.S. lenders passed the latest Federal Reserve capital exams, but they’re bound to be more stressful next time; the country’s consumer prices rose 2.1% in May, intensifying a standoff between the central bank and bond investors.

Capital Calls: SoftBank Arm-twisting

22 Jun 2022

Concise views on global finance: The UK government may be eyeing desperate measures to keep SoftBank-owned chip group Arm's IPO in London.

DSM stocks up on ingredients trend with Swiss deal

31 May 2022

The $29 bln Dutch producer of food supplements is swallowing family-owned Firmenich for shares and 3.5 bln euros in cash. That boosts its appeal with consumer groups seeking to manipulate taste, smell and texture. By making concessions on governance, DSM has got a decent price.